Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971866 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL387453 | 0.85 | — | — | |
| SCHEMBL235856 | 0.85 | — | — | |
| SCHEMBL154974 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL13833159 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL10483535 | 0.85 | ALOX15 (0.44) | ALDH1A1KDM4EPKMSIGMAR1HRH3 | |
| SCHEMBL3947885 | 0.84 | KDM4E (0.38) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL477222 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL11139073 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL3970199 | 0.82 | ALDH1A1 (0.70) | ALDH1A1KDM4EKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2024-05-16 | — | — | US | claimed |
| US-20230416258-A1 | BENZODIAZEPINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-12-28 | — | — | US | claimed |
| EP-4242210-A1 | NEW BENZODIAZEPINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | China Pharmaceutical University (CN) | 2023-09-13 | — | — | EP | claimed |
| CN-116507628-A | Novel benzodiazepine compound, preparation method and application thereof | 中国药科大学 | 2023-07-28 | — | — | CN | claimed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | claimed |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN KETTERING INST CANCER RES (US) | 2023-03-02 | — | — | US | claimed |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2021-05-13 | — | — | US | claimed |
| CN-112358483-A | Novel benzodiazepine compound, preparation method and application thereof | 中国药科大学 | 2021-02-12 | — | — | CN | claimed |
| EP-3208615-B1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-10-09 | — | — | EP | claimed |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-07-02 | — | — | US | claimed |
| CN-1333754-A | Benzoheterocycles and their use as MEK inhibitors | WARNER LAMBERT CO (US) | 2002-01-30 | — | — | CN | claimed |
| EP-1150950-A2 | ANTHRANILIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2001-11-07 | — | — | EP | claimed |
| EP-1144362-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| EP-1144371-A1 | BENZENESULPHONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001005390-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000041505-A2 | ANTHRANILIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000041994-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 1851/4885KDM4E 4392/4885KMT2A 3897/4885 |
| US-20230416258-A1 | BENZODIAZEPINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GABRA4, GABRA1, GABRA5 | ALDH1A1 1744/4885KDM4E 1651/4885KMT2A 2078/4885 |
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | ALDH1A1 1998/4885KDM4E 4480/4885KMT2A 4309/4885 |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 1352/4885KDM4E 3119/4885KMT2A 2799/4885 |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | ALDH1A1 1998/4885KDM4E 4480/4885KMT2A 4309/4885 |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 1352/4885KDM4E 3119/4885KMT2A 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.